FimmCyte
FimmCyte AG is a Swiss pre-clinical biotech developing a proprietary antibody immunotherapy platform for chronic fibro-inflammatory diseases, with lead candidate FMC2 — a first-in-class non-hormonal, disease-modifying treatment for endometriosis — licensed to Gedeon Richter for global development.
- Company typePrivate
- Founded2022
- HeadquartersBasel, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingServices
What FimmCyte does
FimmCyte AG is a Swiss pre-clinical biotechnology company headquartered in Basel with a secondary office in Copenhagen, founded in 2022 as a spin-off from the University of Zurich and University Hospital Zurich by Valentina Vongrad (CSO) and Mohaned Shilaih (CEO). The company develops a proprietary antibody immunotherapy platform that targets a specific protein overexpressed in diseased cells, enabling precise elimination of fibrotic tissue while preserving healthy areas. Its lead candidate, FMC2, is a first-in-class, non-hormonal, disease-modifying antibody treatment for endometriosis designed to address the root pathology rather than symptoms, with additional pipeline assets FMC3 and FMC4 extending the platform to other chronic fibro-inflammatory indications such as organ, kidney, and heart fibrosis.
The company serves an underserved patient population — approximately 190 million women globally are affected by endometriosis, where existing treatments are limited to hormonal therapies and surgery with significant side effects — and serves pharmaceutical partners as its commercial counterparties. FimmCyte's business model is structured around licensing and milestone payments rather than direct product sales: it pursues non-dilutive institutional funding (Venture Kick, UZH Life Sciences Fund, BioInnovation Institute, Innosuisse, Gebert Rüf, BaseLaunch, InnoBooster) for R&D while monetizing through strategic pharma partnerships such as the February 2026 Gedeon Richter option-to-license agreement granting exclusive global development and commercialization rights to FMC2.
As a pre-clinical stage company with 1-10 employees, FimmCyte has no current product revenue. Its go-to-market is conducted through biotech partnering events (e.g., BIO-Europe Spring), scientific publications, and direct outreach to pharmaceutical partners, with leadership combining scientific founders and senior pharma executives (Chairman Dr. Markus Kalousek, ex-Novartis VP Partnering; CMO Dr. Maureen Cronin, former Bayer VP Women's Health and Vifor EVP) to support both R&D and eventual commercialization.
FimmCyte firmographics
Firmographics- Name
- FimmCyte
- Legal name
- FimmCyte AG
- Website
- https://www.fimmcyte.com/
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- FimmCyte AG is a Swiss pre-clinical biotech developing a proprietary antibody immunotherapy platform for chronic fibro-inflammatory diseases, with lead candidate FMC2 — a first-in-class non-hormonal, disease-modifying treatment for endometriosis — licensed to Gedeon Richter for global development.
- Ownership category
- akta.pro rank
FimmCyte industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
Keywords
Where FimmCyte is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
FimmCyte business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Licensing and milestone payments: FimmCyte is a pre-clinical stage biotech with no current revenue. The company plans to generate revenue through licensing agreements with pharmaceutical partners, receiving development and commercial milestone payments along with tiered royalties on net sales. The Gedeon Richter agreement includes pre-agreed terms for milestone payments and royalties.
- Non-dilutive funding and grants: The company has received multiple non-dilutive funding sources including convertible loans from UZH Life Sciences Fund (CHF 1M), BioInnovation Institute (EUR 1.3M), and grants from Venture Kick (CHF 150,000), Innosuisse, and Gebert Rüf Foundation.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
FimmCyte product offering
Product offeringCore offering
FimmCyte is a pre-clinical biotechnology company developing a proprietary antibody immunotherapy platform for chronic fibro-inflammatory diseases. Its lead candidate, FMC2, is a first-in-class, non-hormonal, antibody-based therapy designed to address the root cause of endometriosis by targeting a well-established fibrosis marker. The pipeline extends to FMC3 and FMC4 for additional fibro-inflammatory indications, with all assets built on the same proprietary platform that enables precise elimination of diseased tissue while preserving healthy areas.
Product overview
FimmCyte is a pre-clinical stage biotech company developing a pipeline of disease-modifying treatments for chronic fibro-inflammatory diseases, primarily focused on women's health. The company's portfolio consists of FMC2 (lead clinical candidate for endometriosis in IND-enabling/clinical candidate ready stage), FMC3 (fibro-inflammatory diseases in lead optimization), and FMC4 (additional pipeline asset). All candidates are built on FimmCyte's proprietary antibody immunotherapy platform, which leverages the discovery of a specific protein marker of fibrosis to enable precise targeting and elimination of diseased tissue while preserving healthy areas. The platform represents a first-in-class, non-hormonal approach to treating endometriosis and other fibro-inflammatory conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- FMC2 First-in-class, non-hormonal, antibody-based therapy designed to address the root cause of endometriosis through disease-modifying mechanisms. FMC2 recognizes a well-established marker of fibrosis and has demonstrated antifibrotic effects in preclinical studies. Licensed to Gedeon Richter under an exclusive option-to-license agreement covering global rights exercisable prior to first-in-human clinical studies.
- FMC3 Next-generation antibody therapy in lead optimization stage targeting fibro-inflammatory diseases, extending FimmCyte's proprietary antibody platform beyond endometriosis to additional chronic conditions.
- FMC4 Additional pipeline antibody asset for chronic fibro-inflammatory diseases, part of FimmCyte's portfolio of next-generation therapies designed to transform patient care by providing effective, targeted treatments.
Quantifiable outcome
- Potential to be one of the first disease-modifying treatments for endometriosis, addressing root cause rather than symptoms
Companies that use FimmCyte
Customer profileSegments2 records
Ideal customer profiles2 records
FimmCyte technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
FimmCyte partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- Gedeon RichterflagshipFimmCyte entered a strategic research collaboration and option-to-license agreement with Gedeon Richter, a leading Hungarian pharmaceutical company with EUR 2.2bn in 2024 sales. Both companies will conduct joint R&D toward first-in-human clinical studies for FMC2. Gedeon Richter holds an exclusive option on global rights exercisable before first clinical trial initiation. FimmCyte is eligible to receive development and commercial milestone payments along with tiered royalties on net sales under pre-agreed terms.
- BaseLaunchcoreHealthcare accelerator supporting FimmCyte through its biotech ecosystem, providing funding and development support.
- University Hospital Zurich (USZ)coreAcademic partner and founding institution of FimmCyte spin-off, providing research capabilities and clinical expertise.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
FimmCyte competitors and assessment
Company assessmentBroad incumbents
- FibroGen: Clinical-stage biotech developing pamrevlumab (anti-CTGF antibody) for fibrotic diseases including IPF and pancreatic cancer. Broad incumbent with a directly comparable monoclonal antibody approach to fibrosis, a key mechanism aligned with FimmCyte's anti-fibrotic platform.
- Ferring Pharmaceuticals: Private global pharmaceutical company specializing in reproductive health, women's health, and gastroenterology, with a meaningful endometriosis therapeutic franchise. Broad incumbent in women's health and a potential strategic partner comparable to Gedeon Richter for FimmCyte's FMC2 development.
- Organon & Co. Women's health-focused pharmaceutical spinoff from Merck with established endometriosis and uterine fibroid products. Broad incumbent in women's health therapeutics with the commercial infrastructure and provider relationships that FimmCyte would need to access for any direct commercialization.
- AbbVie: Global pharmaceutical company with the leading endometriosis franchise (Orilissa/elagolix, Oriahnn) and a broader women's health portfolio. Broad incumbent in the endometriosis therapeutic area against which FimmCyte's FMC2 would compete commercially if approved.
- Galapagos NV: European biotech with a historical fibrosis pipeline including ziritaxestat and other IPF candidates, and an active push into immunology. Broad incumbent in the fibro-inflammatory space relevant to FimmCyte's platform expansion strategy.
- Bayer: Global pharmaceutical company with a significant women's health franchise including Visanne (dienogest) for endometriosis. Broad incumbent with established commercial infrastructure in endometriosis that FimmCyte's CMO Dr. Cronin helped build during her tenure as VP of Women's Health at Bayer.
- Boehringer Ingelheim: Global pharmaceutical company with a leading fibrosis franchise, including nintedanib (Ofev) approved for idiopathic pulmonary fibrosis and other fibrotic diseases. Broad incumbent in the broader fibro-inflammatory space where FimmCyte's platform could expand beyond endometriosis.
Direct peers
- ObsEva: Swiss-based clinical-stage women's health biotech historically focused on endometriosis (linzagolix) and uterine fibroids. Direct peer as a small-cap, Swiss-headquartered biotech developing novel therapeutics for endometriosis, although ObsEva has faced significant restructuring.
- Myovant Sciences (Sumitomo Pharma): Women's health-focused biotech (now part of Sumitomo Pharma) that developed relugolix, approved for endometriosis and uterine fibroids. Directly comparable as a focused women's health therapeutic company targeting endometriosis, representing the most advanced commercial-stage competitor to FimmCyte's FMC2.
- Pliant Therapeutics: Clinical-stage biotech developing antibody-based therapies for fibrosis, with an integrin-targeting platform addressing fibro-inflammatory diseases. Directly comparable to FimmCyte's antibody immunotherapy approach for fibro-inflammatory indications, including organ fibrosis targets that overlap with FimmCyte's FMC3/FMC4 pipeline expansion ambitions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
FimmCyte social profiles
Digital presenceFimmCyte financial estimates
Financial estimateRevenue estimate
Valuation estimate
FimmCyte leadership team
Management profileNumber of profiles
Profiles5 records
FimmCyte funding detail
Funding detailFunding overview
Funding rounds7 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FimmCyte M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FimmCyte
What does FimmCyte do?
FimmCyte is a pre-clinical biotechnology company developing a proprietary antibody immunotherapy platform for chronic fibro-inflammatory diseases. Its lead candidate, FMC2, is a first-in-class, non-hormonal, antibody-based therapy designed to address the root cause of endometriosis by targeting a well-established fibrosis marker. The pipeline extends to FMC3 and FMC4 for additional fibro-inflammatory indications, with all assets built on the same proprietary platform that enables precise elimination of diseased tissue while preserving healthy areas.
Is FimmCyte a public or private company?
FimmCyte is a private company. It is classified as venture growth investor backed and is currently operating.
When was FimmCyte founded?
FimmCyte was founded in 2022. It employs 1 to 10 people.
Where is FimmCyte based?
FimmCyte is headquartered in Basel, Switzerland, in the Europe region.
How does FimmCyte make money?
Two revenue lines are on record. Licensing and milestone payments are the primary driver. The others are non-dilutive funding and grants.
Who are FimmCyte's main competitors?
Broad incumbents on record are FibroGen, Ferring Pharmaceuticals, Organon & Co., AbbVie, Galapagos NV, Bayer and Boehringer Ingelheim. Direct peers are ObsEva, Myovant Sciences (Sumitomo Pharma) and Pliant Therapeutics.
Does FimmCyte have an API?
No public API is recorded for FimmCyte.
What industry is FimmCyte in?
FimmCyte's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325413 and its SIC code is 2835.